All News

A 3-year registry found dupilumab controlled atopic dermatitis (AD) in most children, though those under 6 years were likelier to stop treatment.

Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.

Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.

Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.

Topical ruxolitinib prescribing in Medicare Part D surged through 2024, but its cost per day runs 16 times higher than generic tacrolimus.

Baseline biopsies separated 16 patients who later developed hepatocellular carcinoma from 32 matched controls a median 6.1 years ahead.

Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.

Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.

Overlapping COVID-19 and flu symptoms make diagnosis hard, says Trinity Health's Tammy Lundstrom, who outlines prevention and vaccine guidance.

Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.

Medicare's cell and gene therapy payment gap remains, with hospitals absorbing costs as insurers limit coverage.

Congress's Mental Health TALK SAFE Act could expand telepsychiatry access by establishing permanent telehealth prescribing and licensing rules.

CDC data show cancer deaths declining as lung cancer treatment and detection advance, with new KRAS-targeted therapies showing early promise.

Nonadherence to semaglutide for obesity worsened once out-of-pocket costs passed roughly $75 per 30-day supply among commercially insured adults.

All 50 states have applied for CMS's GENEROUS Model, a Medicaid drug pricing program expected to save $64.3 billion over the next decade.

Diabetes care improves when support adapts to real-life changes, removing barriers and sustaining daily habits beyond reminders, education, and one-time interventions.

Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.

Logistic regression beats machine learning to predict autoimmune hepatitis recurrence after liver transplantation.

A new blood test for adults as young as 40 years arrives as employers and insurers still treat Alzheimer disease as an old-age condition.

Itch and skin appearance outranked safety for 300 US adults with chronic hand eczema, but cancer risk came next.

Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.

Systematic review finds no ready blood biomarkers for psoriasis biologics, but IL-17A/IL-17F and beta-defensin 2 show promise for precision medicine.

Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.

Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.

Activated memory B cells were already enriched at treatment end in the 5 of 21 patients who later cleared HBsAg

Specialty pharmacy leaders will gather in National Harbor for inSPire2026, tackling cell and gene therapy access, AI, and high-cost drug pricing.

ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.

The study’s primary end point of event-free survival demonstrated a 49% reduction in mortality risk between the blinatumomab and control cohorts.